MENU
+Compare
HBIO
Stock ticker: NASDAQ
AS OF
Aug 7 closing price
Price
$0.51
Change
+$0.03 (+6.25%)
Capitalization
184.01M

HBIO Harvard Bioscience Forecast, Technical & Fundamental Analysis

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development... Show more

Industry: #Biotechnology
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HBIO with price predictions
Aug 07, 2025

HBIO in upward trend: 10-day moving average moved above 50-day moving average on July 23, 2025

The 10-day moving average for HBIO crossed bullishly above the 50-day moving average on July 23, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 62 cases where HBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

HBIO moved above its 50-day moving average on August 05, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where HBIO advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HBIO moved out of overbought territory on July 28, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HBIO as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HBIO turned negative on August 01, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HBIO broke above its upper Bollinger Band on July 23, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HBIO entered a downward trend on July 22, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.530) is normal, around the industry mean (24.599). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.610) is also within normal values, averaging (43.219).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

HBIO is expected to report earnings to fall 50.00% to 0 cents per share on August 11

Harvard Bioscience HBIO Stock Earnings Reports
Q2'25
Est.
$0.00
Q1'25
Est.
$-0.01
Q4'24
Beat
by $0.01
Q3'24
Missed
by $0.04
Q2'24
Missed
by $0.05
The last earnings report on May 13 showed earnings per share of 0 cents, meeting the estimate of 0 cents. With 302.27K shares outstanding, the current market capitalization sits at 184.01M.
A.I. Advisor
published General Information

General Information

a manufacturer of apparatus and scientific instruments

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
84 October Hill Road
Phone
+1 508 893-8999
Employees
416
Web
https://www.harvardbioscience.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KBSTF13.80N/A
N/A
Kobe Steel, Ltd.
ELST0.01N/A
N/A
Electronic Systems Technology, Inc.
WACMF4.59N/A
N/A
Wacom Co., Ltd.
MVLY15.55-0.07
-0.45%
Mission Valley Bancorp
MTCPY11.00-0.16
-1.43%
MTR Corporation Ltd.

HBIO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with IRMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then IRMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
+6.55%
IRMD - HBIO
46%
Loosely correlated
-1.92%
A - HBIO
37%
Loosely correlated
+0.66%
RVTY - HBIO
36%
Loosely correlated
+0.65%
ICUI - HBIO
36%
Loosely correlated
+2.62%
ANGO - HBIO
35%
Loosely correlated
+1.55%
More